Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
US8969414B2 · kind B2 · utility
4Cited by
13References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 5, 2010 |
| Grant date | Mar 3, 2015 |
| Priority date | — |
| Expiry date | Aug 16, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0019
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.